Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
E.S. Enema is a saline osmotic laxative used for rapid bowel cleansing. It is typically administered rectally as a preoperative bowel preparation method, such as before hemorrhoidectomy or other anorectal surgeries, and for the relief of occasional constipation. The product is developed and manufactured by E.S. Ilac in Turkey. Its mechanism of action involves the use of sodium phosphate salts (sodium dihydrogen phosphate and disodium hydrogen phosphate) to create an osmotic gradient in the intestinal lumen. This gradient draws water into the colon, increasing intraluminal volume, softening the stool, and stimulating peristalsis to facilitate evacuation. In clinical trials conducted by Saglik Bilimleri Universitesi, E.S. Enema has been evaluated for its impact on postoperative outcomes, including pain levels and patient comfort, compared to oral laxative solutions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on E.S. Enema.